Two FDA decisions define Praxis now
- Two lead drugs are under FDA review, with relutrigine due September 27, 2026 and ulixacaltamide due January 29, 2027.
- The company had about $1.4 billion in cash and investments at March 31, 2026, enough to fund plans into 2028.
- Praxis still has no product sales, so approval and launch execution matter more than current revenue.
- EMBOLD enrollment is complete, setting up broad DEE data for relutrigine in Q4 2026.
- Q1 operating expenses were about $106 million as R&D and launch spending rose.
Approval is the main gate
Praxis has moved from a pure clinical trial story to a company waiting on FDA decisions. Relutrigine has priority review for seizures tied to SCN2A and SCN8A developmental and epileptic encephalopathies, with a target decision date of September 27, 2026. Ulixacaltamide is under review for essential tremor, with a target decision date of January 29, 2027.
The bull case is simple. If both drugs are approved, Praxis could start product sales for the first time and show that its brain drug platforms can produce real medicines. The company also finished enrollment in the EMBOLD study for relutrigine in a broader DEE group, with data expected in Q4 2026. If positive, that could support a wider label later.
The bear case is also clear. The FDA can still reject either application, ask for more data, or slow the process with an advisory committee meeting. A PDUFA date is only the FDA target date for a decision, not a promise of approval. Praxis also has to build a sales force, win payer access, and teach doctors how to use the drugs.
No sales yet, big launch build
Praxis does not yet make money from product sales. It spends on research, clinical trials, manufacturing, and now commercial launch work. The company funds this with cash raised from stock offerings and other capital markets activity.
Its work is split across two platforms. Cerebrum makes small molecule drugs, including ulixacaltamide, relutrigine, and vormatrigine. Solidus makes antisense oligonucleotides, which are genetic medicines designed to change how certain disease-linked genes are expressed.
The near-term model only works if at least one lead drug gets approved and sells well enough to justify the new spending. In Q1 2026, Praxis had about $106 million of operating expenses, including about $78 million for R&D and about $28 million for G&A. Management says the $1.4 billion cash balance at March 31, 2026 funds operations into 2028.
Four shots on brain disorders
Relutrigine
Relutrigine is under FDA priority review for seizures linked to SCN2A and SCN8A DEEs. Its September 27, 2026 decision date is the closest major approval event.
Ulixacaltamide
Ulixacaltamide is under FDA review for essential tremor after positive Phase 3 Essential3 results. Its target FDA decision date is January 29, 2027.
Vormatrigine
Vormatrigine targets focal onset seizures. POWER1 topline data are expected in Q2 2026, and the result will help show whether this can be a larger epilepsy program.
Elsunersen
Elsunersen is the lead Solidus program for SCN2A gain-of-function DEE. Praxis announced positive EMBRAVE Part A data in April 2026 and is enrolling the EMBRAVE3 registrational study.
Early Solidus ASO programs
PRAX-080, PRAX-090, and PRAX-100 are preclinical ASO programs. They add future optionality, but they are still far from approval.
One business, two platforms
Praxis reports one operating segment: CNS drug development. The mix below uses Q1 2026 R&D expense categories from the 10-Q, not revenue segments, because the company has no product sales.
What could break the story
FDA rejection or delay
High impact · Medium oddsPraxis needs FDA approval before it can sell relutrigine or ulixacaltamide. A Complete Response Letter, extra study request, or negative advisory committee vote would push out revenue and hurt the stock case.
First launch misses
High impact · Medium oddsPraxis has not launched a product before. Even with approval, sales may disappoint if doctors wait, payers restrict access, or patients stop treatment. The company is spending now on sales, marketing, distribution, and inventory before it knows the launch result.
POWER1 data falls short
Medium impact · Medium oddsVormatrigine is an important next pipeline asset. The key question is whether POWER1 shows enough placebo-adjusted seizure reduction with a safety profile doctors will accept. Weak data would narrow the pipeline story.
Cash burn rises faster than planned
Medium impact · Medium oddsPraxis has a large cash balance, but it is still losing money. Q1 2026 net loss was $92.6 million, and spending is rising as the company prepares for launches and runs late-stage trials. If launches are delayed, future financing after 2028 could dilute shareholders.
Broad DEE expansion disappoints
Medium impact · Medium oddsThe finished EMBOLD enrollment sets up an important Q4 2026 readout for relutrigine in a broader DEE population. Positive data could support a supplemental NDA in 2027. Weak or mixed data would limit the market expansion case.
In one breath
Does Praxis Precision Medicines have any approved drugs?
No. As of the Q1 2026 filing, Praxis had not generated product sales and its candidates were in development or awaiting regulatory approval.
What are the next big PRAX catalysts?
The main events are POWER1 data for vormatrigine in Q2 2026, the relutrigine FDA decision on September 27, 2026, EMBOLD broad DEE data in Q4 2026, and the ulixacaltamide FDA decision on January 29, 2027.
Why does Praxis have so much cash?
Praxis raised capital through public stock offerings, including a January 2026 offering with about $621.2 million in net proceeds. The company reported about $1.4 billion in cash, cash equivalents, and marketable securities at March 31, 2026.